Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
Monthly Prescribing Reference5 天
Elinzanetant Reduces Hot Flashes Caused by Breast Cancer Therapy
Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.
Bayer's Elinzanetant Meets Primary, Secondary Endpoints In Phase III OASIS 4 Breast Cancer ...
(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating the ...
The American Journal of Managed Care5 天
Elinzanetant Excels in Phase 3 Study for Vasomotor Symptom Relief
Trial confirms elinzanetant's efficacy and safety in addressing vasomotor symptoms caused by adjuvant endocrine therapy in ...
Daily2 天
New research confirms link between perceived stress and psoriasis relapse
Innovative research has provided compelling evidence that perceived stress can directly trigger the relapse of psoriatic skin ...
来自MSN4 天
A New Ozempic? Researchers Develop New Weight Loss Drug That Doesn't Cause Nausea
The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...
pharmaphorum5 天
Bayer cues up filings for rival to Astellas’ menopause drug
rounding out a trio of phase 3 trials that the German pharma group has been running in support of the oral neurokinin 1, 3 antagonist as a treatment for VMS. In the study, elinzanetant ...